Hand holding cannabis extract. (Source: Adobe Stock. Generated by AI)
  • Tilray Medical, a division of cannabis powerhouse Tilray Brands (TSX:TLRY), has partnered with Molteni, an Italian pharmaceutical firm focused on pain therapies and substance dependence, to broaden the availability of its cannabis extracts across Italy
  • Tilray Brands is a cannabis, beverage, wellness and entertainment company supporting more than 40 brands in more than 20 countries
  • Tilray stock has given back 48.03 per cent year-over-year and 93.28 per cent since May 2021

Tilray Medical, a division of cannabis powerhouse Tilray Brands (TSX:TLRY), has partnered with Molteni, a top Italian pharmaceutical firm focused on pain therapies and substance dependence, to broaden the availability of its cannabis extracts across Italy.

This content has been prepared as part of a partnership with Tilray Brands Inc., and is intended for informational purposes only.

Under the partnership, Tilray Medical subsidiary, FL Group, will provide medical cannabis education throughout Molteni’s network of pharmaceutical, scientific and medical professionals in Italy.

Founded in 1892 and headquartered in Florence, Molteni maintains operations in more than 40 countries and benefits from in-house manufacturing, research and development, regulatory, supply chain and commercial capabilities, opening the door for future partnerships with Tilray down the line.

The new partnership complements Tilray’s existing operations in Italy, in addition to presences in Germany, Portugal, Poland and the United Kingdom, with European cannabis revenue growing by 112 per cent in fiscal 2025.

Leadership insights

“This partnership reflects our commitment to advancing patient care through strategic collaboration,” Rajnish Ohri, Tilray Brands’ Managing Director, International, said in Wednesday’s news release. “By combining FL Group’s regulatory and distribution capabilities with Molteni’s scientific leadership, we are not only expanding access to high-quality, EU-GMP certified cannabis therapies for patients across Italy but also prioritizing medical cannabis education for pain therapies. Through Molteni’s extensive network of healthcare professionals, we aim to empower practitioners with the knowledge and resources needed to support patients seeking effective pain management solutions.”

About Tilray Brands

Tilray Brands is a cannabis, beverage, wellness and entertainment company supporting more than 40 brands in more than 20 countries.

Tilray stock (TSX:TLRY) las traded at C$1.32. The cannabis stock has given back 48.03 per cent year-over-year and 93.28 per cent since May 2021.

Join the discussion: Find out what everybody’s saying about this Canadian cannabis stock on the Tilray Brands Inc. Bullboard and check out the rest of Stockhouse’s stock forums and message boards.

Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.


More From The Market Online

@ the Bell: TSX lifted by strong earnings from Big Six banks

The TSX Index added more than 1 per cent on Thursday driven by strong earnings from Canada’s Big Six banks.

Market Open: Salesforce Gains, EQB Buys PC Financial, Copper Slips | Dec 04, 2025

TSX rises 0.36% as Salesforce jumps 2% and EQB acquires PC Financial. Dow dips, gold edges higher, copper and Bitcoin fall.

Buzz on the Bullboards: Cannabis stock split, major financing, and battery breakthrough

Inflation concerns, lofty valuations, and growing uncertainty around returns from have prompted investors to reassess their AI exposure.